Results of a phase III study investigating polatuzumab vedotin combined with chemotherapy for first line treatment of diffuse large b-cell lymphoma.
Home / Resource Library / Polatuzumab vedotin + R-CHP vs R-CHOP for frontline treatment of DLBCL: results from the phase III POLARIX trial